EBMT-EHA CAR-T 2019 | The limitations of immunotherapy with CAR T-cells
Elaine Vickers, PhD, of Science Communicated Ltd., Manchester, UK, reports that despite the promising clinical results CAR T-cell therapy have demonstrated in hematological malignancies, not all treated patients manage to go into complete remission. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Dr Vickers highlights the current limitations of CAR T-cell therapy and states that the next step will be the improvement of its efficacy in different solid tumors. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
Get great new content delivered to your inboxSign up